Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1995-8-3
|
pubmed:abstractText |
Because a variety of mechanisms may generate pain in neuropathic pain syndromes, conventional clinical trial methods may fail to identify some potentially useful drugs; a drug affecting just a single mechanism may work in too few patients to yield a statistically significant result for the trial. To test a previous clinical observation that approximately one-quarter of patients with painful diabetic neuropathy appear responsive to clonidine, we conducted a formal clinical trial of transdermal clonidine in painful diabetic neuropathy patients using a 2-stage enriched enrollment design. In the first stage (study 1), 41 patients with painful diabetic neuropathy completed a randomized, 3-period crossover comparison of transdermal clonidine (titrated from 0.1 to 0.3 mg/day) to placebo patches. Twelve apparent responders from study I were entered into the 'enriched enrollment' second stage (study II), consisting of an additional 4 double-blind, randomized, 1-week treatment periods with transdermal clonidine and placebo. Study I showed that in the overall group of 41 patients, pain intensity differed little during clonidine and placebo treatment. In study II, however, the 12 apparent responders from study I had 20% less pain with clonidine than placebo (95% confidence interval (CI): 4-35% pain reduction; P = 0.015), confirming that their pain was responsive to clonidine. None of the 3 consistent clonidine responders who were tested with the alpha-adrenergic blocker phentolamine had relief of pain, suggesting that clonidine's pain relief is not mediated by a decrease in sympathetic outflow. A post-hoc analysis of many variables suggested that patients who described their pain as sharp and shooting may have a greater likelihood of responding to clonidine.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0304-3959
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
60
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
267-74
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7596622-Administration, Cutaneous,
pubmed-meshheading:7596622-Adult,
pubmed-meshheading:7596622-Aged,
pubmed-meshheading:7596622-Aged, 80 and over,
pubmed-meshheading:7596622-Clonidine,
pubmed-meshheading:7596622-Cross-Over Studies,
pubmed-meshheading:7596622-Diabetic Neuropathies,
pubmed-meshheading:7596622-Double-Blind Method,
pubmed-meshheading:7596622-Female,
pubmed-meshheading:7596622-Follow-Up Studies,
pubmed-meshheading:7596622-Humans,
pubmed-meshheading:7596622-Male,
pubmed-meshheading:7596622-Middle Aged,
pubmed-meshheading:7596622-Pain,
pubmed-meshheading:7596622-Placebos,
pubmed-meshheading:7596622-Research Design
|
pubmed:year |
1995
|
pubmed:articleTitle |
Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design.
|
pubmed:affiliation |
Neurobiology and Anesthesiology Branch, National Institutes of Health, Bethesda, MD 20892, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|